Navigation Links
Hikma CEO Interviewed on Half-Year 2011 Results
Date:8/25/2011

LONDON, August 25, 2011 /PRNewswire/ --

Hikma Pharmaceuticals reports lower-than-expected 3.2% increase in revenues for the first half but maintains its full-year outlook.

The international drug developer says that political unrest in the MENA region disrupted month-on-month sales in some key countries like Egypt and Tunisia.

In an interview with financial broadcaster http://www.cantos.com, Hikma CEO Said Darwazah says that production is back to normal and that in spite of difficulties the group managed to grow the business organically by 3% in the MENA region.

While the group's Multi-Source Injectables division, which was acquired from Baxter Healthcare last year, was impacted by transaction delays, Mr Darwazah remains confident the business "will be breaking even" by the fourth quarter.

Hikma's CEO also makes clear that further acquisitions in emerging markets are in the pipeline.  In the interview he reiterates full-year guidance of 7% organic growth and 20% overall business growth.

The interview and transcript are available now on http://www.cantos.com/company/Hikma%20Pharmaceuticals.

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email amanda.alexander@cantos.com or phone +44-(0)207-936-1372.



'/>"/>
SOURCE Hikma Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. HIKMA - 2008 Preliminary Results Interview With CEO
2. Hikma - Half Year Results Interviews With CEO and CFO
3. Hikma Expands its Global Injectables Business - Live Webcast
4. Hikma Expands its Global Injectables Business Through the Acquisition of Baxter Healthcare Corporations Multi-Source Injectables Business
5. China Sky One Medical, Inc. Interviewed in The China Perspective
6. Access Pharmaceuticals CEO Interviewed on Financial Website
7. AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
8. Cord Blood America CEO Matthew Schissler Interviewed on International Successes
9. Smith & Nephew CEO Interviewed on Q2 2011 Results
10. STALLERGENES: Strong Sales Growth in 1st Half-Year: up 12% Full-Year Guidance Maintained
11. STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... as part of its corporate rebranding initiative announced today. The bold new look ... its reach, as the company moves into a significant growth period. , It will ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... ... 09, 2017 , ... At its national board meeting in North Carolina, ... University’s Departments of Physics and Astronomy, has been selected for membership in ARCS ... for the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating ...
(Date:10/7/2017)... 2017  The 2017 Nobel Prize in Chemistry ... Dubochet, Joachim Frank and Richard ... microscopy (cryo-EM) have helped to broaden the ... community. The winners worked with systems manufactured by ... highly resolved, three-dimensional images of protein structures that ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
Breaking Biology News(10 mins):